A Phase I, Multicenter, Open-label, First-in Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Tumors (EGRET)
Advanced Solid Tumours
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
VOON PEI JYE
CONTACT
SC: Erfan Bin Salbi, Lim Li Fang
General line: 082 – 276666
CRC: 082-276820 (Tel)
082-276823 (Fax)
Tiong Lee Len, Admin Manager
leelen.crc@gmail.com (Email)
(Facebook)
An Open Label, Multicenter, Safety and Efficacy Phase II/III Study of PRL3-Zumab in Solid Tumors Patients
Unresectable solid tumors, second line
Beacon Hospital
PRINCIPAL INVESTIGATOR
Dr Tho Lye Mun
CONTACT
03- 7787 2830
tholm@beaconhospital.com.my
Kuala Lumpur Hospital (HKL)
PRINCIPAL INVESTIGATOR
IBTISAM MUHAMAD NOR
CONTACT
General line: 04-2225 333
CRC: 042225 767 / 2225 762 / 2225 766 / 2225 586
Dr. Yoon Chee Kin, Ketua Jabatan
dryoonck@moh.gov.my (email)
Sister Zarina Bt Che Umar, Admin Manager
zarinacu@gmail.com (Email)
University of Malaya Medical Centre (UMMC)
PRINCIPAL INVESTIGATOR
ADLINDA
CONTACT
MADIHAH
Contact no: 03-79492120
Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRAS G12C Mutant Solid Tumors
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
VOON PEI JYE
CONTACT
SC: Angelyna Michelle
General line: 082 – 276666
CRC: 082-276820 (Tel)
082-276823 (Fax)
Tiong Lee Len, Admin Manager
leelen.crc@gmail.com (Email)
Facebook
A Multicenter, Randomized, Double-Blind, Phase 2, Basket Study of MK-4280A, a Coformulation of Favezelimab (MK-4280) with Pembrolizumab (MK-3475) in Selected Solid Tumors
Sultan Ismail Hospital, Johor Bahru
PRINCIPAL INVESTIGATOR
CHEN MAY FENG
CONTACT
SC: Ezzah Aisyah Najwa Dzulkafli
General line: 082 – 276666
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
Ng Ming Ruey
CONTACT
SC: Nur Izzah Binti Mohammed,
Nur Fatin Nabilah Ngu Binti Nur Hisyamuddin Ngun